Want to see IN:INDSWFTLAB full AI Analyst Report?
Top Page
Ind-Swift Laboratories Ltd.
(INDSWFTLAB)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹250.00
▲(175.63% Upside)
Action:Reiterated
Date:07/11/26
The score is held back primarily by weakening cash generation (negative operating and free cash flow in 2024–2026) and recent revenue/EBIT deterioration, despite a materially improved balance sheet. Technicals are supportive due to a strong uptrend, but overbought RSI/Stoch readings add pullback risk. Valuation is a headwind given the high P/E (46.85) with no dividend yield support.
Positive Factors
Improved balance sheet
Management materially reduced leverage and grew equity through 2024–2026, creating a stronger capital base. Lower debt and higher equity increase financial flexibility, reduce refinancing risk, and provide a durable buffer to absorb shocks and support strategic investments.
Negative Factors
Weak cash generation
Persistent negative operating and free cash flow across 2024–2026 creates a structural funding gap. This reduces the company's ability to self-fund operations and growth, heightens liquidity and refinancing risk, and constrains durable investment in R&D, manufacturing or market expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet
Management materially reduced leverage and grew equity through 2024–2026, creating a stronger capital base. Lower debt and higher equity increase financial flexibility, reduce refinancing risk, and provide a durable buffer to absorb shocks and support strategic investments.
Read all positive factors
Ind-Swift Laboratories Ltd. (INDSWFTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹21.43B
Dividend YieldN/A
Average Volume (3M)7.30K
Price to Earnings (P/E)46.9
Beta (1Y)0.94
Revenue Growth226.01%
EPS Growth-84.17%
CountryIN
Employees47
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.26
Shares Outstanding86,961,555
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ind-Swift Laboratories Ltd. Business Overview & Revenue Model
Company Description
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, includ...
How the Company Makes Money
null...
Ind-Swift Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.41B | 5.62B | 12.81B | 12.07B | 10.39B |
| Gross Profit | 1.90B | 2.74B | 4.13B | 4.40B | 4.10B |
| EBITDA | 450.97M | 2.85B | 7.82B | 2.36B | 2.35B |
| Net Income | 414.15M | 2.50B | 4.21B | 475.97M | -21.49M |
Balance Sheet | |||||
| Total Assets | 16.73B | 14.38B | 14.60B | 18.24B | 18.01B |
| Cash, Cash Equivalents and Short-Term Investments | 4.72B | 4.82B | 4.94B | 231.54M | 333.68M |
| Total Debt | 205.01M | 408.41M | 166.22M | 8.62B | 9.53B |
| Total Liabilities | 2.89B | 2.65B | 6.48B | 11.42B | 12.00B |
| Stockholders Equity | 13.84B | 11.73B | 9.36B | 6.82B | 6.01B |
Cash Flow | |||||
| Free Cash Flow | -1.08B | -898.80M | -2.08B | 1.82B | 1.32B |
| Operating Cash Flow | -198.64M | -254.74M | -1.63B | 1.95B | 1.50B |
| Investing Cash Flow | -1.28B | -1.10B | -1.23B | -133.68M | 47.72M |
| Financing Cash Flow | 1.47B | 692.05M | 6.99B | -1.86B | -1.41B |
Ind-Swift Laboratories Ltd. Technical Analysis
Positive
90.70
Price Trends
165.52
Positive
152.77
Positive
127.03
Positive
Market Momentum
20.07
Negative
84.78
Negative
86.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Positive. The current price of 90.7 is below the 20-day moving average (MA) of 197.77, below the 50-day MA of 165.52, and below the 200-day MA of 127.03, indicating a bullish trend. The MACD of 20.07 indicates Negative momentum. The RSI at 84.78 is Negative, neither overbought nor oversold. The STOCH value of 86.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDSWFTLAB.
Ind-Swift Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹23.19B | 22.36 | ― | ― | 17.97% | 126.79% | |
73 Outperform | ₹12.37B | 14.02 | ― | 0.37% | 7.67% | 6.74% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹21.43B | 46.85 | ― | ― | 226.01% | -84.17% | |
52 Neutral | ₹27.23B | -351.17 | ― | ― | 6.64% | -177.19% | |
50 Neutral | ₹30.18B | -61.81 | ― | 0.58% | -7.91% | -153.72% | |
43 Neutral | ₹24.01B | -24.23 | ― | 0.08% | 10.73% | -31.79% |
* General Sector Average
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
246.40
139.90
131.36%
IN:HIKAL
Hikal Limited
244.75
-96.75
-28.33%
IN:INDOCO
Indoco Remedies Limited
260.15
-58.92
-18.47%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
617.65
71.66
13.12%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
569.95
-103.40
-15.36%
IN:VENUSREM
Venus Remedies Limited
1,735.10
1,259.10
264.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.